

Amivantamab CHRYSLIS

PRELIMINARY SCORE

CURATIVE



NON-CURATIVE



ADJUSTMENTS

Quality of life



Not qualified for an ESMO-MCBS credit



Serious and disabling adverse effects




Other adjustments



Amivantamab CHRYSLIS

SCORE

CURATIVE



Overall Survival / Disease-Free Survival / Pathological Complete Response

NON-CURATIVE



Overall Survival



Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

INFORMATION

Tumour type: Thoracic Malignancies
 Therapeutic Indication: Advanced NSCLC with activating EGFR exon 20 insertion mutations, after failure of platinum-based therapy
 Experimental Arm: Amivantamab
 Control Arm: Single arm

